Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy

European Heart Journal

Volumn 36, Issue 37, 2015, Pages 2530-2540

  Guo, Jian ^a,b   Mihic, Anton ^a,b   Wu, Jun ^a,b   Zhang, Yuemei ^a,b   Singh, Kaustabh ^a,b   Dhingra, Sanjiv ^a,b   Weisel, Richard D ^a,b   Li, Ren Ke ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; CNPY2; Heart failure; HIF 1 ; Hypertrophy; p53

Indexed keywords

ANGIOGENIC FACTOR; CANOPY 2 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; UNCLASSIFIED DRUG; CANOPY 2 PROTEIN, MOUSE; CNPY2 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION; TRANSGENIC MOUSE; VASCULARIZATION; ANGIOGENESIS; ANIMAL; AORTA; C57BL MOUSE; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART VENTRICLE FUNCTION; HUMAN; LIGATION; METABOLISM; PHYSIOLOGY; TUNEL ASSAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; AORTA; CARDIOMYOPATHY, HYPERTROPHIC; CONSTRICTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HUMANS; IN SITU NICK-END LABELING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; TUMOR SUPPRESSOR PROTEIN P53; VENTRICULAR FUNCTION;

EID: 84943567607     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv294     Document Type: Article

References (18)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
2. Oka T, Komuro I. Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J Off J Jpn Circ Soc 2008;72(Suppl. A): A13-A16.
3. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010;128:191-227.
4. Balakumar P, Jagadeesh G. Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?. Pharmacol Res Off J Ital Pharmacol Soc 2010;62:365-383.
5. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 1998;273: 11995-11998.
6. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34-44.
7. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007;446:444-448.
8. Guo J, Zhang Y, Mihic A, Li S-H, Sun Z, Shao Z, Wu J, Weisel RD, Li R-K. A secreted protein (Canopy 2, CNPY2) enhances angiogenesis and promotes smooth muscle cell migration and proliferation. Cardiovasc Res 2015;105:383-393.
9. Bornhauser BC, Lindholm D. MSAP enhances migration of C6 glioma cells through phosphorylation of the myosin regulatory light chain. Cell Mol Life Sci 2005;62: 1260-1266.
10. Bornhauser BC, Olsson P-A, Lindholm D. MSAP is a novel MIR-interacting protein that enhances neurite outgrowth and increases myosin regulatory light chain. J Biol Chem 2003;278:35412-35420.
11. Do HT, Tselykh TV, Makela J, Ho TH, Olkkonen VM, Bornhauser BC, Korhonen L, Zelcer N, Lindholm D. Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). J Biol Chem 2012;287:12602-12611.
12. Hatta K, Guo J, Ludke A, Dhingra S, Singh K, Huang M-L, Weisel RD, Li R-K. Expression of CNPY2 in mouse tissues: quantification and localization. PLoS ONE 2014;9: e111370.
13. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 2003;285:H1261-H1269.
14. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613.
15. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991;69:483-490.
16. Felkin LE, Birks EJ, George R, Wong S, Khaghani A, Yacoub MH, Barton PJR. A quantitative gene expression profile ofmatrixmetalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. J Heart Lung Transplant 2006;25: 1413-1419.
17. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target?. Circulation 2004;109:1580-1589.
18. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA 2002;99:8219-8224.